Exciting News from ISPE South Central Chapter! 🚀 https://scispe.org/ We are thrilled to unveil our brand-new website! A huge thank you to our Sponsors and Board of Directors for their invaluable support in making this happen. 🌟 Interested in deepening your engagement with us? We're looking for members who are eager to become Sponsors or join one of our dynamic Committees. Help us get your company's name out there and grow the Texas and Oklahoma Life Science Ecosystem's!! 🏌️♂️ Don't miss out on our annual events! Mark your calendars for our upcoming Houston Golf Tournament and the preceding Happy Hour. It's a fantastic opportunity to network and have some fun! 👀 Explore all that our new site has to offer at [insert website URL]. Have suggestions for what else you'd like to see? We’d love to hear from you! #ISPE #Networking #ProfessionalGrowth #EngineeringExcellence Greg Trujillo Evan Ottenweller Ranson Stillwell Dwayne Ariola, CMRP Dave Burton Tim Glasson Joseph Sullivan, P.E. Yuk Chun Chiu Patricia Stewart Flaherty MSc Ivan Kuncheff Bill Shwaiko David Teer Harold Woods Joseph Payne
ISPE SC Chapter’s Post
More Relevant Posts
-
@Matt Wetzel @Julie Tibbets An excellent overview of where we're at and where we could be heading as the complex legal, regulatory and compliance requirements are ever changing for the life sciences, medtech, and diagnostic industries.
A Look Ahead in Life Sciences: What We Are Tracking in Q2 2024 and Beyond | Insights & Resources | Goodwin
goodwinlaw.com
To view or add a comment, sign in
-
Use MVA partner meetings to raise awareness of your technology, competencies and expertise among potential partners and customers in the Medicon Valley cluster! We are fully booked in Q2 – see some of the upcoming MVA partner meetings co-organized with dedicated MVA member companies below – but we are open for business from mid September and onwards. In other words, don´t wait too long if you plan to use the MVA partner event concept to raise awareness of your special competencies and expertise and reach out to potential partners and customers in the region. We already have the first Q3 meeting in the pipeline and Q3 and Q4 are typically quite busy! Upcoming partner meetings: 4th of June: Addressing the complexity of immunogenicity testing with BioAgilytix https://lnkd.in/gJKnZit9 7th of June: The strategic considerations to successfully navigate the regulatory complexities of targeted medicines with Cencora PharmaLex https://lnkd.in/dcWhGX4j 11th of June: How to Ensure Compliance with EU GMP Annex 1 – a practical perspective with Cencora PharmaLex https://lnkd.in/dnguxS_E 12th of June: Rationalizing the Preclinical-Clinical Hurdle – How to Overcome the Toxicology Exposure Challenge with Quotient Sciences https://lnkd.in/dvuS2k57 19th of June: A Strategic CDMO Approach in Drug Development and Commercialization with FAREVA https://lnkd.in/dcERAm26 Learn more about the three different partner event concepts, the attractive pricing and risk sharing model and how to learn more on the links below MVA Good Morning Meetings: https://lnkd.in/dEn96V3c MVA Boost Seminars: https://lnkd.in/eMATzSDi MVA Full Day conferences: https://lnkd.in/d4m9nYeD Any questions, reach out to Director, Member Engagement and Communication, David Munis Zepernick, dz@mva.org https://lnkd.in/dwericeY
Introduction to MVA partner events (Good Morning Meetings, Boost Seminars and Full Day Conferences)
https://www.youtube.com/
To view or add a comment, sign in
-
🔍 HOW READY DO YOU NEED TO BE FOR THE EU JCA? It all depends on your role: 👩💼 Product Team Lead with EMA filings for oncology products in H1 2025: Essential for your and the cross-functional team to be fully prepared with preparations being mid-way. 🌍 EU Policy Lead in a company not impacted until 2028: Understanding the JCA's implications for future planning is crucial. 🤝 BD&L Lead reporting on JCA impact for Due Diligence: Deep understanding of JCA's influence on asset acquisition is vital. 💼 Market Access Lead in a company acquiring late-stage assets: Strategic insights for evidence generation and submission planning are indispensable. At Inbeeo, we offer tailored Lunch & Learn sessions on EU JCA Readiness. Whether introductory or in-depth, we will provide strategic insights for evidence generation and submission planning for effective Market Access. Reach out for a chat to discuss your session's specifics with our specialists: Christel Jansen, Sara Cueva Oemer, Lucy Forrester, and Konstantina Malliou! #MarketAccess #EUJCA #Strategy #Inbeeo
To view or add a comment, sign in
-
-
💊 Supply chain disruptions continue to cause shortages of critical medications worldwide. Everstream Analytics' Director of Life Sciences and Healthcare, Henry Ames, is speaking at the PDA - Parenteral Drug Association Southeast Fall Conference on October 25. Henry will share how #AI is revolutionizing risk management to protect and optimize global #pharmaceutical and #medical supply chains. Register here ➡ https://lnkd.in/gNiPwXh3
PDA Southeast Chapter: Fall Conference
pda.org
To view or add a comment, sign in
-
📌 While #cGMP plays a crucial role in ensuring drug quality and consistency, many biopharmaceutical developers overlook its early adoption. 🔎 Discover why incorporating cGMP chemicals earlier can minimize risks and accelerate your development milestones. Learn about the seamless transition from research phase to clinical production, the significance of quality supplier relationships, and how planning for compliance standards upfront can save time and resources down the line while ensuring a smooth and successful drug development journey. Learn More: 👉 https://lnkd.in/dihFXtQ7 #Fisherscientificeu #DrugDevelopment #Biopharma #QualityControl
Fisher Scientific Europe
eu.fishersci.com
To view or add a comment, sign in
-
Helpful webinar coming up from our CTDMO Services
Accelerated Monoclonal Antibody Development: Advance from Transfection to GMP Drug Substance in 9 Months
event.on24.com
To view or add a comment, sign in
-
Nice to be back on the conference scene and seeing so many familiar faces. If you are here, come and see us for a chat on how we can support the Bioanalysis and Biomarker needs for your clinical trial. #clinicaltrials #clinicalresearch #bioanalysis #COGUK
Say hello to the team at COG UK 2024! If you're attending COG UK in London today/tomorrow, be sure to visit stand 25 where the Alderley Analytical team will be on-hand to discuss our specialist bioanalytical services to support your drug development programmes through discovery, pre-clinical safety testing and clinical development. 📍Leonardo Royal Tower Bridge, London 🗓 20th - 21st February 2024 👋 Find us at Stand 25
To view or add a comment, sign in
-
-
Join #IQVIA ’s Launch Excellence web-series, wherein we explore the question of what it takes to achieve Launch Excellence in Oncology. Oncology continues to be one of the growth drivers within the biopharmaceutical industry. Globally, the oncology market is forecasted to reach $440 billion by 2028, growing at 14-17% CAGR with the addition of an estimated 100 new treatments over the next 5 years. #oneIQVIA #connectedintelligence #drivinghealthcareforward https://lnkd.in/e3J8vaPs
Event Lobby (EVENT: 4602012)
event.on24.com
To view or add a comment, sign in
-
Ziccum had an intensive schedule of meetings at Nordic Life Science Copenhagen Nov 29–30. CEO Ann Gidner and Chairman Fredrik Sjövall were invited to partnering meetings with new interested prospects and attended valuable follow-up meetings. CEO: ‘the knowledge of our offering is high and we expect to pursue many dialogues initiated here. It’s very satisfying we could move dialogues to a more strategic level with large corporation counterparts. We’d like to thank our industry colleagues for an engaging, well-attended event” https://lnkd.in/dq4pff64 #nlsdays #biologics #biopharmaceuticals #formulatiion #vaccines #thermostablevaccines
Ziccum move dialogues to next level at NLS Copenhagen
ziccum.com
To view or add a comment, sign in